What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Surgery
Caroline Robert mainly focuses on Internal medicine, Melanoma, Surgery, Ipilimumab and Oncology.
Her Internal medicine study frequently links to related topics such as Gastroenterology.
Her Melanoma research includes themes of Immunology and Monoclonal.
As part of the same scientific family, Caroline Robert usually focuses on Surgery, concentrating on Placebo and intersecting with Maintenance therapy and Sorafenib.
Her Ipilimumab research incorporates elements of Enterocolitis, Faecalibacterium prausnitzii, Survival rate, Nivolumab and Adjuvant therapy.
As a member of one scientific family, Caroline Robert mostly works in the field of Pembrolizumab, focusing on Talimogene laherparepvec and, on occasion, PD-L1 inhibitor.
Her most cited work include:
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. (10562 citations)
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5899 citations)
- PD-1 blockade induces responses by inhibiting adaptive immune resistance (3713 citations)
What are the main themes of her work throughout her whole career to date?
Caroline Robert mostly deals with Internal medicine, Melanoma, Oncology, Ipilimumab and Cancer.
Caroline Robert interconnects Gastroenterology and Surgery in the investigation of issues within Internal medicine.
Her Surgery study deals with Hazard ratio intersecting with Placebo and Phases of clinical research.
Her Melanoma study incorporates themes from Immunology and Immunotherapy.
Her Oncology study also includes
- Trametinib, which have a strong connection to MEK inhibitor,
- Clinical trial that intertwine with fields like Randomized controlled trial.
Her biological study spans a wide range of topics, including Nivolumab and Survival analysis.
She most often published in these fields:
- Internal medicine (58.44%)
- Melanoma (46.93%)
- Oncology (39.88%)
What were the highlights of her more recent work (between 2019-2021)?
- Internal medicine (58.44%)
- Oncology (39.88%)
- Melanoma (46.93%)
In recent papers she was focusing on the following fields of study:
Her main research concerns Internal medicine, Oncology, Melanoma, Cancer and Pembrolizumab.
In general Internal medicine study, her work on Clinical trial, Adverse effect and Ipilimumab often relates to the realm of In patient, thereby connecting several areas of interest.
She focuses mostly in the field of Adverse effect, narrowing it down to topics relating to Gastroenterology and, in certain cases, Toxicity.
Her study explores the link between Oncology and topics such as Immunotherapy that cross with problems in CTLA-4.
Specifically, her work in Melanoma is concerned with the study of Vemurafenib.
She has included themes like Biomarker, Mortality rate and Retrospective cohort study in her Cancer study.
Between 2019 and 2021, her most popular works were:
- Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. (205 citations)
- A decade of immune-checkpoint inhibitors in cancer therapy. (161 citations)
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. (131 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Caroline Robert mainly investigates Internal medicine, Oncology, Melanoma, Clinical trial and Pembrolizumab.
Her research brings together the fields of Placebo and Internal medicine.
Her work carried out in the field of Oncology brings together such families of science as Survival rate, Trametinib, Dabrafenib and Immunotherapy.
Her Melanoma study combines topics in areas such as V600E, Clinical endpoint and MEK inhibitor.
Her Clinical trial research includes elements of Immune checkpoint and Survival analysis.
The concepts of her Hazard ratio study are interwoven with issues in Cancer staging, Vemurafenib and Phases of clinical research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
